

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com



Anti-EGFR [cet.Hum (Cetuximab - humanized; hC225)] Standard Size Ab03275-10.3

This antibody was created using our proprietary Fc Silent[™] engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This full-length reformatted human antibody was made using the variable domain sequences of the original Human scFv format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgG1, Fc Silent[™], Kappa

Clone Number: cet.Hum (Cetuximab - humanized; hC225)

Alternative Name(s) of Target: ERBB1; ERBB; ErbB-1, Erb-B1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

UniProt Accession Number of Target Protein: P00533

Published Application(s): WB, Block, ELISA, FC

Published Species Reactivity: Human

Immunogen: The original antibody was generated by grafting CDR loops of cetuximab on framework regions derived from type 3 (VH3 and VL3 kappa) human germline sequences to obtain recombinant VH and VL domains linked together with a flexible linker [(Gly4Ser)3] to form a scFv.

Specificity: This antibody recognizes human EGFR. The epidermal growth factor receptor is the cellsurface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands.

Application Notes: The binding characterization of this humanized scFv version of cetuximab to human EGFR was done using ELISA. This antibody can recognize human EGFR from lysates of A-431 and MCF-7 cells in western blot. The scFv version was able to recognize EGFR on over-expressing cancer cells (A-431) but failed to detect cancer cells with low levels of EGFR (MCF-7 cells) in a flow cytometric experiment. The binding affinity of this scFv version was reported to be 9 fold lower than that of the parental cetuximab, but still it was strong enough for the successful recognition of human EGFR expressing cells. This antibody can be used to block cancer cell surface receptors and inhibit their downstream signaling (PMID: 29185855). **Antibody First Published in:** Banisadr et al. Production of a germline-humanized cetuximab scFv and

evaluation of its activity in recognizing EGFR- overexpressing cancer cells. Hum Vaccin Immunother. 2018; 14(4): 856–863. PMID:29185855

Note on publication: Describes the generation of the humanized scFv version of a therapeutic antibody

cetuximab.

Product Form

Size: 200 μg Purified antibody.
Purification: Protein A affinity purified
Supplied In: PBS with 0.02% Proclin 300.
Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at - 20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.